A quiet but consequential reordering of global technology investment is under way, and 10x Genomics — once a flagship of the American genomics instrumentation boom — has become one of its most visible casualties.
The California-based company's financial deterioration is stark. Consumables revenue, the recurring engine that sustains any instrumentation business, has collapsed from $493.4 million to $122.2 million. The annualized quarterly revenue run-rate has fallen to approximately $87.2 million, down from the $610.8 million pace that once justified its premium valuation. Operating losses widened to $41.5 million even as gross margins improved from 67% to 72% — a paradox that reveals a cost structure too rigid to adapt to a shrinking global customer base.
Cash reserves have contracted from $482 million to $393.4 million, narrowing the strategic window available to management. At current burn rates, the runway is finite, and the pressure to articulate a credible path to profitability is intensifying on both sides of the Atlantic.
A Global Capital Rotation, Not a Local Correction
The timing of 10x Genomics' difficulties is inseparable from a broader macro-financial shift that is reshaping technology valuations across every major market. Institutional investors in New York, London, Tokyo, and Zurich have been systematically rotating capital toward what analysts now term "core AI infrastructure" — companies whose revenues are directly and structurally tied to building the physical and computational backbone of artificial intelligence.
NVIDIA, the American chip designer whose graphics processors have become the defining hardware of the AI era, has seen its market capitalisation surpass $3 trillion, rivalling the GDP of major economies. Applied Materials and TSMC, the Taiwan-based semiconductor giant that manufactures the chips powering AI systems globally, have similarly commanded premium valuations as the infrastructure layer of the AI economy consolidates.
The consequence for companies that sit adjacent to this thesis — using AI as a feature rather than existing as AI's foundation — has been a valuation vacuum. Life science instrumentation companies like 10x Genomics generate biological data that can feed machine learning pipelines, and their investor communications have leaned heavily on AI integration narratives. But global capital markets are now drawing a sharp distinction between selling the shovels for the AI gold rush and merely using AI-adjacent tools.
The Pattern Extends Across Continents
The compression is not confined to American genomics companies. 17 Education & Technology Group, a Chinese AI-adjacent edtech firm, saw its adjusted net loss margin deteriorate from -9.5% to -191% over the same period, a figure that signals the repricing is global and crosses sector boundaries. From European healthtech startups to Asian precision medicine platforms, companies that built their growth narratives around AI integration — rather than AI infrastructure — are facing the same rerating pressure.
European life science markets, traditionally more insulated from US capital cycles due to their reliance on public research funding and national health system procurement, are not immune. The European Investment Bank and national innovation funds have ramped genomics investment in recent years, but private market valuations in the sector are tracking the American correction with a lag. Analysts at several European investment banks have begun revising growth multiples for genomics and diagnostics platforms accordingly.
In Asia, where genomics has been a strategic national priority — China's BGI Group built one of the world's largest genomic sequencing operations, and South Korea and Japan have invested heavily in precision medicine infrastructure — the question is whether state-backed capital can insulate domestic players from global multiple compression, or whether the rerating will ultimately prove inescapable.
The Multiple Compression Test
Analysts tracking EV/Revenue multiples across global technology subsectors are watching a specific threshold: if AI-adjacent sectors — including genomics, edtech, and proptech — show more than 30% greater multiple compression than core AI infrastructure companies on a revenue-growth-adjusted basis over the next two quarters, it would constitute evidence of a structural reallocation rather than a cyclical correction.
The distinction matters enormously for policy as well as investment. Governments from the United Kingdom to South Korea have made genomics and life science technology central pillars of their national industrial strategies, often citing AI integration as the multiplier that justifies public investment. If the market is correct that AI-adjacent life science companies represent a structurally weaker investment category than core AI infrastructure, those national strategies may require reassessment.
What Comes Next
For 10x Genomics and its global peers, the path forward narrows to a few credible options: demonstrate a genuine AI-native product architecture that moves beyond data generation into predictive biological insight; pursue consolidation with complementary platforms to achieve the scale that justifies continued institutional coverage; or accept a fundamental rerating and rebuild on a lower-cost, profitability-first operating model.
None of these paths is straightforward in the current environment. Credit conditions remain tight globally, cross-border M&A in sensitive technology sectors faces heightened regulatory scrutiny — particularly for genomics companies, given the geopolitical sensitivity of biological data — and the window for growth-stage capital raises has narrowed significantly since 2021.
The broader lesson may be this: in a world where capital is concentrating with unusual speed around a single transformative technology, companies that cannot make an unambiguous claim to the core of that technology will find themselves priced accordingly — regardless of geography, regardless of scientific merit, and regardless of the genuine long-term value embedded in their platforms.
Sources:
1 Yahoo Finance, "How Expanded RCS Use In Regulated Messaging At Twilio (TWLO) Has Changed Its Investment Story" (March 22, 2026)
2 Nasdaq, "Got $1,000? This Under-the-Radar AI Stock Could Be a Future 10-Bagger" (March 21, 2026)
3 Yahoo Finance, "This Investor Exited a $22 Million GRAIL Stake Before a 50% One-Day Stock Crash Last Month" (March 22, 2026)
4 Nasdaq, "Want $1 Million in Retirement? Invest $10,000 in These 2 AI Stocks and Hold for 10 Years." (March 21, 2026)
5 Yahoo Finance, "CNOOC Names Huang Yongzhang as Chief Executive Officer" (March 23, 2026)